Jci_page_head_homepage_01 Jci_page_head_homepage_02
Masayuki Mori, Guixin Li, Ikuro Abe, Jun Nakayama, Zhanjun Guo, Jinko Sawashita, Tohru Ugawa, Shoko Nishizono, Tadao Serikawa, Keiichi Higuchi, Seigo Shumiya
Published in Volume 116, Issue 2
J Clin Invest. 2006; 116(2):395–404 doi:10.1172/JCI20797
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 6
Fdft1 mutations and reduced FDFT1 activity in SCRs.

(A) Alignment of regions of Fdft1 cDNA sequence derived from SCR and ACI rats. Nucleotide substitutions at positions 204, 486, and 588 in SCR Fdft1 are indicated in bold. The I196K amino acid substitution caused by 588T→A is also shown. (B) Comparison of FDFT1 activity in rat liver microsome, as determined by amount of postsqualene metabolites converted from [3H]farnesyl diphosphate (mean dpm ± SD). *P < 0.05 versus ACI rats (Student’s t test). Western blot image of rat hepatic FDFT1 is shown at the top.